TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ISONOVA

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

ISONOVA

ST13

US500000098510322

Classe

9, 42

Pedido

98510322

Registro

7702936

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

16

Atualização mais recente

25/02/2025

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

9, 42

Data de depósito

19/04/2024

Data de registro

25/02/2025

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

25/02/2025

Última transação

25/02/2025

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

London, GB

Examinador

RENNIE, GABRIELLE

Localização atual

FILE REPOSITORY (FRANCONIA)

Titulares e representantes

Titulares

Isomorphic Labs Limited

Representantes

Lindsay B. Allen Perkins Coie LLP

Classificação técnica

Classes Nice

Classe 9Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 9

Downloadable software for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; downloadable computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for predicting protein structure, discovering drugs, designing drug candidates, biologic product development, and pharmaceutical product development; downloadable computer software, computer programs and computer software algorithms for manipulating received or inputted data generated in a virtual space in connection with artificial intelligence methods, machine learning methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, and predictive assistance technologies, for protein structure prediction, l drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; downloadable computer software for conducting therapeutic product research and development; downloadable computer software for discovering, optimizing and developing drugs; downloadable computer software for designing and developing drug candidates

Classe 42

Software as a service (SAAS) services featuring software for protein structure prediction, drug discovery, drug candidate design, biological product development, and pharmaceutical product development; software as a service (SAAS) services featuring software using artificial intelligence, machine learning, deep learning, or reinforcement learning for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; platform as a service (PaaS) services featuring software for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; platform as a service (PaaS) services featuring software using artificial intelligence, machine learning, deep learning, and reinforcement learning for protein structure prediction, drug discovery, development of biologic materials, development of biologic products, and pharmaceutical product development; advanced product research, design and development in the field of artificial intelligence for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; research and development in the fields of artificial intelligence, machine learning, deep learning, and reinforcement learning technologies for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; technology research in the field of artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; providing online, non-downloadable computer software platforms for protein structure prediction, drug discovery, drug candidate design, biologic material development, , and pharmaceutical product development; providing online, non-downloadable computer software platforms using artificial intelligence, machine learning, deep learning, or reinforcement learning for protein structure prediction, drug discovery, drug candidate design, biological produce development, and pharmaceutical product development; testing of computing methods, computer software algorithms, computer software, and computer hardware for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; scientific, pharmaceutical, biotech, medical, and artificial intelligence research; scientific research in the field of computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for medical research, pharmaceutical research, biotech research, protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; product research and development; medical, pharmaceutical, biotech, and scientific research in the field of protein structure prediction, drug discovery, drug candidate design, biologic product development, pharmaceutical product development, and computational biology; scientific and technological services, namely, scientific research in the fields of analytics and data mining, data analysis, data transformation, data visualization, statistical analysis, artificial intelligence, machine learning, virtual reality, science, chemistry, medicinal chemistry, physics, biology, and digital biology, all for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer aided data analysis for scientific research purposes in the fields of artificial intelligence, machine learning, deep learning, reinforcement learning, building neural networks, data tree search, high performance computing, distributed computing, cloud computing, analytics and data mining, virtual reality, augmented reality, chemistry, medicinal chemistry, physics, biology, and digital biology, all for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer modelling services; technical or scientific services for the analysis of compositions of matter; technical consulting in the field of pharmaceutical studies; drug discovery, drug design, optimization and development services; research and development of therapeutic products; drug discovery, optimization and development services; medical and scientific services in the field of pharmaceuticals, namely, therapeutic and diagnostic candidate design services

Publicações

Histórico de despachos e eventos da marca no USPTO.

16 publicações encontradas

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

25/02/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

25/02/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

07/01/2025

PUBO

PUBLISHED FOR OPPOSITION

07/01/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

01/01/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

14/12/2024

XAEC

EXAMINER'S AMENDMENT ENTERED

14/12/2024

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

14/12/2024

GNEA

EXAMINERS AMENDMENT E-MAILED

14/12/2024

CNEA

EXAMINERS AMENDMENT -WRITTEN

14/12/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

12/11/2024

GNRT

NON-FINAL ACTION E-MAILED

12/11/2024

CNRT

NON-FINAL ACTION WRITTEN

12/11/2024

DOCK

ASSIGNED TO EXAMINER

04/11/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/10/2024

NWAP

NEW APPLICATION ENTERED

19/04/2024

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ISONOVA ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.